Description of Collaborative Activity: |
The National Institutes of Health (National Institute on Drug Abuse; NIDA) Serves as Co-Chair with the Food and Drug Administration (FDA) on this inter-agency subcommittee addressing drug overdose. NIDA participates on its constituent working groups whose topics include: drafting and implementation of the HHS Overdose Prevention Strategy; expanding access to contingency management; addressing pharmacy availability of buprenorphine; determining the public health impact of kratom scheduling; and improving clinician education on controlled substance prescribing. |
Type of Collaborative Activity: |
Committee, Advisory Group, or Work Group
|
HHS Agency Collaborators on this Activity: |
AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA, OASH, ASPE |
